Page Loading...
Layout Table~~~~1433~1433~~
Personalized Medicine 2007~
Published by Select Biosciences, April 2007

This report presents the latest industry analysis of the emerging field of Personalized Medicine. There is increasing interest in this field driven by the development of a number of molecular diagnostics-based tests that determine a patient’s genetic predisposition to a given disease—such as cancer, or to adverse drug reactions (ADRs).~Published by Select Biosciences, April 2007

This report presents the latest industry analysis of the emerging field of Personalized Medicine. There is increasing interest in this field driven by the development of a number of molecular diagnostics-based tests that determine a patient’s genetic predisposition to a given disease—such as cancer, or to adverse drug reactions (ADRs).

Personalized Medicine is growing rapidly—this report documents the various tests currently available, their market opportunity and hurdles to their market adoption. In addition, Select Biosciences presents in this report the current pipeline of personalized medicine-based tests in various different therapeutic areas.

This report is the only report on the marketplace that presents a market analysis of the personalized medicine space based upon a proprietary market survey performed recently by Select Biosciences. The market analysis addresses qualitative market trends and quantitative market metrics, and pinpoints the opportunities and hurdles in this market.

Topics Covered in this Report

Companies Profiled in this Report

Table of Contents~Personalized Medicine Market Report 2007 (Single User Print Version)|1001|Personalized Medicine Market Report 2007 (Electronic Site License)|1002|~1433~3131~~
Theranostics Report 2007-2012~
Published by Visiongain, January 2007

Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it a lot easier for you and your company.

This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process of drug development offers you and your company clear opportunities. This emerging field is generating interest from the healthcare industry and regulatory bodies, with the associated market expanding continually as the importance of theranostics is recognised.

~Untitled DocumentPublished by Visiongain, January 2007

Key questions remain over theranostics. How can your company secure key successes and ideals in personalized medicine - aiming the right drug at the right person and at the right time. Plus with increased FDA regulation, how can we guarantee that that specific drug is safe for that individual. These issues are not going away, but one report can make it a lot easier for you and your company.

This report delivers to you a clear understanding of the commercial prospects of theranostics. The fusion of drug therapy and diagnostics, with the purpose of optimising efficacy and safety, as well as streamlining the process of drug development offers you and your company clear opportunities. This emerging field is generating interest from the healthcare industry and regulatory bodies, with the associated market expanding continually as the importance of theranostics is recognised.

Theranostic solutions are playing an increasingly important role in pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, theranostics is paving the way towards the long-held goal of personalised medicine, to the benefit of patients and payers. Theranostics has also received encouraging support from regulators such as the FDA. Pharmaceutical, diagnostics and biotechnological companies cannot afford to overlook this rapidly emerging field. So you should be sure you corner your percentage of the market immediately.

Theranostics 2007-2012 examines the market for theranostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses theranostics in the context of the wider diagnostics market. In addition to consultation with experts in industry, this research involved a detailed study of documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting and SWOT analyses. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, this report concentrates on the following essential aspects of the theranostics sector:Why you should buy this report: Visiongain predicts that all aspects of theranostics will exhibit strong growth in revenues from 2007-2012, with significant investments being made by far-sighted companies in the pharmaceutical, diagnostics and biotechnological sectors. Although still in its early stages of commercial development, theranostics will increasingly gain acceptance from stakeholders in healthcare. Successful participating companies will benefit as a result, gaining early market prominence from high-value products. But which areas of theranostics will that be? Find out today by ordering your executive copy of Theranostics 2007.

Companies mentioned in the report

A&G Pharmaceutical
Abbott Laboratories
Affymetrix
Amorfix Life Sciences
AstraZeneca
Axis-Shield
Bayer
Biogen Idec
Bristol-Myers Squibb
Cambridge Theranostics
Chiron
Clinical Data
CyGene
DakoCytomation
Digene
DNAPrint Genomics
Epigenomics
EXACT Sciences
Fornix Theranostics
Gemini (Eurona)
Genaissance Pharmaceuticals
Genentech
Genetic Vectors
Gen-Probe
Glaxo Wellcome
HBV Theranostica
Hyseq
IGEN International
ImClone Systems
Innogenetics
Investigen
Itsi-Biosciences
Kingo Diagnostika
Lpath Therapeutics
Merck & CO.
Millennium Predictive Medicine
Myriad Genetics
Neighborhood Connections
NGI
Novartis
Oncogene Science
Organon Teknika
PeptiFarma
PGxHealth
PharmaNetics
Pronto Diagnostics
Provalis
Quidel
Roche
Seapro Theranostics International B.V
Sequenom
The Boston Consulting Group
TheraNostics GmbH
Tibotec-Virco
Ventana Medical Systems
Visible Genetics
Vysis
Wyeth


Table of contents | Sample Pages ~Theranostics Report 2007-2012 (Single User License)|781|Theranostics Report 2007-2012 (Departmental License)|782|Theranostics Report 2007-2012 (Company Wide License)|783|~1433~2631~~
Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D~
Companies Products and WW Market, 2004-2009

Published by Takeda Pacific, July 2005

One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

~Companies Products and WW Market, 2004-2009

Published by: Takeda Pacific, July 2005


One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

The study projects the 5-year trends for biomarkers, molecular diagnostics and pharmacogenomic tests used by the drug makers. The report charts the developments of more than 50 companies involved in this dynamic industry.

This report discusses new FDA initiatives to accelerate the approvals of emerging diagnostics and new drugs by integrating biomarkers and pharmacogenomic tests drug development from pre-clinical through the end of clinical trial phases. Companies have responded with new products. Roche’s new microarray test, targets certain gene variants, and tests if patients respond well to 30 or more currently marketed drugs. Tailored therapies such as Herceptin, Gleevec, Erbitux, or Irressa are among a new class of marketed products. They work very effectively, but just for a sub-set of individuals that pass special genetic tests designed for each product. These products signal that the era of personalized medicine has begun.

This study is packed with interesting data and includes more than 66 figures and tables. The tables provide data about technologies, companies, product pipelines, partnerships and more. The study also has additional data such as the worldwide incidence and prevalence of major diseases. The report analyzes partnering deals and includes several years of alliance and M&A data.

Twenty-two selected companies are profiled, with details including contact information, business and product overviews, alliances and patent or other financial details. This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Table of Contents~Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A PDF Single User License|52|Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A Site License|53|~1433~2686~~

Menu Page | Toolbar Page |
Frameset Page | Index Page | Table of Contents
EROL - Electronic Retail Online E-commerce shopping cart software